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Abstract
Background: To date, the influence of milk and dairy products on carcinogenesis remains controversial. However,
lipids of ruminant origin such as conjugated linoleic acids (CLA) are known to exhibit beneficial effects in vitro and
in vivo. The aim of the present study was to determine the influence of milk lipids of different origin and varying
quality presenting as free fatty acid (FFA) solutions on cellular fatty acid distribution, cellular viability, and growth of
human colon adenocarcinoma cells (HT-29).
Methods: FAME of conventional and Alpine milk lipids (MLcon,M L alp) and cells treated with FFA derivatives of milk
lipids were analyzed by means of GC-FID and Ag
+-HPLC. Cellular viability and growth of the cells were determined
by means of CellTiter-Blue
®-assay and DAPI-assay (4’,6-diamidino-2-phenylindole dihydrochloride), respectively.
Results: Supplementation with milk lipids significantly decreased viability and growth of HT-29 cells in a dose- and
time-dependent manner. MLalp showed a lower SFA/MUFA ratio, a 8 fold increased CLA content, and different CLA
profile compared to MLcon but did not demonstrate additional growth-inhibitory effects. In addition, total
concentration and fatty acid distribution of cellular lipids were altered. In particular, treatment of the cells yielded
highest amounts of two types of milk specific major fatty acids (μg FA/mg cellular protein) after 8 h of incubation
compared to 24 h; 200 μMo fM L con (C16:0, 206 ± 43), 200 μMo fM L alp (C18:1 c9, (223 ± 19). Vaccenic acid (C18:1
t11) contained in milk lipids was converted to c9,t11-CLA in HT-29 cells. Notably, the ratio of t11,c13-CLA/t7,c9-CLA,
a criterion for pasture feeding of the cows, was significantly changed after incubation for 8 h with lipids from MLalp
(3.6 - 4.8), compared to lipids from MLcon (0.3 - 0.6).
Conclusions: Natural lipids from conventional and Alpine milk showed similar growth inhibitory effects. However,
different changes in cellular lipid composition suggested a milk lipid-depending influence on cell sensitivity. It is
expected that similar changes may also be evident in other cell lines. To our knowledge, this is the first study
showing a varied impact of complex milk lipids on fatty acid distribution in a colon cancer cell line.
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Background
The incidence for colon cancer world-wide is increasing;
the Western-style diet in particular is considered to be
one of the main risk factors involved in colon cancer
development [1]. In general, the Western-style diet asso-
ciated with a high fat intake is considered to be an
adverse factor. However, the composition of dietary fat
is decisive for an assessment of its nutritional value and
its role in the incidence of cancer [2]. The nutritional
role of milk, dairy products and meat of ruminant origin
also displays this controversy since on the one hand,
these products contain potent chemopreventive and
anticarcinogenic compounds such as branched-chain
fatty acids (BCFA), phospholipids, ether lipids, vitamin
D, and conjugated linoleic acid (CLA) which play a pro-
tective role in colorectal cancer [3,4]. On the other
hand, milk lipids contain high amounts of saturated
fatty acids (SFA) that are associated with an increased
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data supports a role of dietary fat of animal origin with
an increased risk of breast and pancreatic cancer [6,7].
Concerning CLA, however, no significant association
between dietary intake and risk of breast cancer has
been found according to a recent study [8]. CLA from
ruminant origin exhibit an increased potential for antic-
arcinogenic activity in vitro and in vivo [9]. CLA (C18:2;
c/t, t/c, c/c, t/t) display a high variation of positional and
geometrical isomers with conjugated double bonds
depending on the ruminant species, season and the type
of feeding. C9,t11-CLA is the main dietary isomer
(90%). In cows, extensive feeding on herbs and pasture
with a high composition of PUFA (polyunsaturated fatty
acid) increased total CLA amount and CLA precursor
such as C18:1 t11 (VA, vaccenic acid) in milk fat, and
generated different isomers such as t11,c13-CLA [10].
An intensive feeding diet leads to lower CLA content
[11]. To date, only a few studies have investigated the
impact of CLA in its natural form, e.g. in butter fat or
beef tallow in vivo [12-14], and in milk fat or beef
extracts in vitro on cancer [15-17]. Investigations of
nutritional substances relevant to health and diseases in
in vitro models allow a better understanding of potential
effects and the related molecular mechanisms. Remark-
ably, none of the in vitro studies examined the incor-
poration and metabolism of lipid mixtures into cell
lipids to determine whether growth inhibition is asso-
ciated with fatty acid (FA) distribution. Dietary PUFA,
including CLA, have been shown to be effective indu-
cers of cell death [18]. Thus, in this study, we examined
the effects of Alpine milk fat naturally enriched in CLA
and other PUFA in comparison to conventional milk fat
on viability, growth and cellular FA distribution of
highly transformed HT-29 colon adenocarcinoma cells.
This in vitro study model allows an examination of the
positive or negative influence of a complete FA spec-
trum on human health. By supplementation with mix-
tures containing c9,t11-CLA and other PUFA as
anticarcinogenic compounds, this study aims to clarify
the effects of these lipids on colon cancer cells. Previous
study models employed these lipids as pure single iso-
mers. In contrast, herein, complex milk lipids from two
different origins and of varying quality were used to
examine their degree and relevant mode of action.
Methods
Milk samples and fatty acid analysis
During the interventional trial, conventional milk lipids
(MLcon, Braunschweig, Germany) were derived from
German Holstein cows receiving a diet consisting of
50% concentrate and 50% roughage [19]. Alpine milk
lipids (MLalp,S w i t z e r l a n d )w e r ep r e p a r e df r o mt h em i l k
of Simmental x Red Holstein cows kept on summer
pasture without concentrate in the Swiss Alps. At least
8 milk lipid samples from each breed were pooled to
obtain sufficient free fatty acid (FFA) derivative sample
material for the in vitro investigation in HT-29 cells. FA
distribution of the samples was analyzed after transester-
fication of total milk lipids to fatty acid methylesters
(FAME) using methanolic sodium methylate 0.5 N at
room temperature for 20 min. The FA analysis of total
FAME including the distribution of cis/trans-C18:1 iso-
mers required two GC methods. Firstly, FA distribution
of four to twenty-six chain carbon atoms including total
CLA was analyzed using a fused-silica capillary column
with medium polarity (DB-225 MS: 60 m × 0.25 mm i.
d. with 0.25 μm film thickness; Agilent Technologies,
USA) as described previously [20]. Secondly, a fused-
silica capillary column with high polarity (CP-select: 200
m × 0.25 mm i.d. with 0.25 μm film thickness; Varian,
Netherlands) was used to separate octadecenoic acid
methylesters with cis-a n dtrans-configuration under
isothermal conditions at 176°C. The temperature of the
injector and the flame ionization detector was set at
260°C and 270°C for both GC programs, respectively.
H y d r o g e nw a su s e da sac a r r i e rg a s .E v a l u a t i o no ft h e
chromatograms was completed according to the reten-
tion time of known standards with GC solution software
(GC-solution version 2.3 from Shimadzu, Kyoto, Japan).
FAME standards for GC analysis were received from
CPS Chemie (Aachen, Germany), Nu-Chek Prep (Ely-
sian, USA), Sigma (Steinheim, Germany), and Supelco
(Taufkirchen, Germany). Additionally, silver ion-HPLC
(Ag
+-HPLC) was used to separate FAME of CLA iso-
mers as described previously [21]. In brief, LC10A-
HPLC (Shimadzu, Kyoto, Japan) with three silver ion-
impregnated columns (Chrompack ChromSpher 5
Lipids; each: 250 mm × 4.6 mm i.d., 5 μm; Varian,
Netherlands) was used in series followed by the UV
spectrophometric detector SPD-10A at 233 nm (Shi-
madzu, Kyoto, Japan). Isocratic mobile phase containing
hexane/diethyl ether/acetonitril/2-propanol (99.35/0.5/
0.1/0.05, v:v:v:v) served as eluent at a flow rate of 1 mL/
min.
Preparation of milk samples for in vitro experiments
Investigation with natural complex lipids in vitro
requires the presence of FFA (free fatty acids), since
cells cannot absorb triacylglycerides (TAG) [22]. Against
this background, preparation of FFA was conducted by
means of an adapted procedure originally described by
Bligh and Dyer [23]. Milk lipids (100 mg) were dissolved
in 0.75 mL ethanol (96%) and TAG were saponified
with 0.75 mL of ethanolic sodium hydroxide 2 N at 70°
C for 30 min. The solution was neutralized with 1.5 mL
of hydrochloric acid 1 N. FFA were extracted using 1.5
mL chloroform for 5 min under shaking. Two phases
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ide solution and 1.5 mL chloroform. After further shak-
ing (5 min) and centrifugation (2300 × g), the lower
phase was collected. Success of this process was con-
firmed by thin layer chromatography using hexane/
diethyl ether/formic acid (80/20/2, v:v:v). Distribution
and amount of FFA were verified. After transesterfica-
tion to FAME with 2 mL of a methanolic boron trifluor-
ide solution (5%, wt:wt; 100°C, 2 min), the distribution
of FFA was analyzed by means of the two above-men-
tioned GC methods. Additionally, FA including C16:0,
C18:0 and C18:1 c9 were absolutely quantified by GC-
FID (60 m column) using the TAG tritricosanoin as
internal standard (CPS Chemie, Aachen, Germany).
Thereafter, total FFA levels were adjusted to 100 mM in
ethanol. Finally, the FA distribution and amounts of
FFA-MLalp/con in ethanol were measured by GC-FID as
described above. Before usage in cell culture experi-
ments, FFA-MLalp/con solutions were diluted with cell
culture medium to 10 mM.
Cell culture
Human colon adenocarcinoma cells HT-29 were
obtained from the American Tissue Culture Collection
(ATCC) and maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM; 4.5 g/L glucose, 58 mg/L L-glutamine,
without sodium pyruvate; Invitrogen, Darmstadt, Ger-
many) supplemented with fetal bovine serum (10%, v:v;
Biochrom, Berlin, Germany). Cells were cultivated as
subconfluent monolayers in cell flasks (T-25 cm
2 and T-
75 cm
2; Greiner Bio one, Frickenhausen, Germany)
under standard conditions at 37°C in a humidified cul-
ture incubator with 5% carbon dioxide and 95%
humidity.
Cell viability and growth parameters of HT-29 cells
To obtain results of cell viability and growth para-
meters, 8000 cells/well were seeded onto a 96-well
plate (Greiner Bio one, Frickenhausen, Germany) and
were allowed to attach for 24 h. Cells were then trea-
ted with two different types of complex milk lipids
(FFA-MLalp/con). Freshly prepared FFA solutions were
added to a final volume of 200 μL culture medium.
Concentrations of MLcon and MLalp ranging from 5-
250 μM were chosen and incubated for 24 h, 48 h
and 72 h and cell viability and growth parameters
were determined by means of the CTB assay (CellTi-
ter-Blue
®; Promega, Mannheim, Germany) and the
DAPI assay (4’,6-diamidino-2-phenylindole dihy-
drochloride; Carl Roth GmbH, Karlsruhe, Germany),
respectively as previously described [24]. Results of
cell viability and growth were calculated on the basis
of percentage change to medium control containing
0.25% ethanol.
Fatty acid analysis after treatment with milk lipids
Following incubation with 100 μM and 200 μMo f
MLalp/con for 8 h and 24 h in 25 cm
2 flasks, cells were
washed with phosphate-buffered saline (PBS), detached
from the flask by a trypsin/EDTA solution (0.05%/
0.02%) and centrifuged at 700 × g for 5 min at 8°C.
After discarding the supernatant the cell pellet was
resolved in PBS. Protein content was determined by
employing the Bradford method using bovine serum
albumin as standard [25]. Cellular lipids were extracted
with a methanol/chloroform mixture according to Bligh
and Dyer [23]. Tritricosanoin was used as an internal
standard. Derivatization of total lipids was conducted
with 1 mL methanolic sodium hydroxide 0.5 N (100°C,
10 min) followed by addition of 1 mL of a methanolic
boron trifluoride solution (10%, wt:wt; 100°C, 2 min).
FAME were extracted three times with hexane (1 × 2
mL, 2 × 1 mL). Relative and absolute quantitative ana-
lyses of FAME extracts including CLA distribution by
means of GC-FID and Ag
+-HPLC were performed as
described in the section milk samples and FA analysis.
Statistical analysis
All statistical analyses were performed using SPSS statis-
tics, version 17.0 (
©2009 SPSS Inc, Illinois, USA). Results
were presented as means ± SD. Significant effects of
MLalp/con on cell viability and cell growth were assessed
by one-way ANOVA followed by Dunnett’s post hoc test
(comparison to control group). The multiple compari-
sons were conducted with two-way ANOVA (milk type
× FA-concentration) followed by Tukey’s post hoc test
to compare the results of FA analyses after different
treatments. A value of P < 0.05 was taken to indicate
significance.
Results
Characterisation of milk lipids
The FA distribution of MLcon and MLalp showed signifi-
cant differences depending on the types of milk lipids
required to achieve ethanolic FFA-MLcon/alp solutions
(Table 1). FA distribution of MLcon showed high
amounts of SFA (77.7%) and MUFA (monounsaturated
fatty acid) (19.9%) and was characterized by low levels
of PUFA (2.4%) including 0.3% of total CLA. In contrast,
FA distribution of MLalp was characterized by decreased
quantities of SFA (63.0%), higher concentrations of
MUFA (30.3%), and PUFA (6.8%) including 3.2% of total
CLA and, therefore, showed a significantly higher ratio
of PUFA/SFA compared to MLcon. However, concentra-
tions of n-6 PUFA were similar to MLcon,w h e r e a sn - 3
PUFA, C18:1 t11 and CLA were significantly higher by
factors of 3, 10 and 9, respectively (Table 1A). Generally,
the nutritional properties of the milk lipids were similar
with regards to elevated levels of SFA. In contrast, since
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AB
MLcon MLalp MLcon MLalp
FAME [%] Mean SD Mean SD Mean SD Mean SD
C14:0 12.32 ± 0.51
b 9.67 ± 0.25
d 13.09 ± 0.18
a 10.21 ± 0.18
c
C14:1 c9 1.04 ± 0.05
b 0.89 ± 0.03
d 1.15 ± 0.02
a 0.98 ± 0.01
c
C15:0 1.24 ± 0.05
d 1.35 ± 0.02
c 1.47 ± 0.04
b 1.58 ± 0.04
a
C16:0 38.36 ± 1.29
b 26.49 ± 0.89
d 43.50 ± 1.35
a 29.76 ± 0.53
c
C16:1 c9 1.70 ± 0.05
b 1.37 ± 0.04
d 1.97 ± 0.01
a 1.62 ± 0.04
c
C17:0 0.56 ± 0.02
c 0.68 ± 0.01
b 0.68 ± 0.02
b 0.79 ± 0.01
a
C18:0 9.53 ± 1.07 10.19 ± 0.85 9.92 ± 0.22 10.54 ± 0.26
C18:1 c9 14.06 ± 0.65
d 19.79 ± 0.68
b 15.56 ± 0.19
c 21.71 ± 0.27
a
C18:1 c11 0.46 ± 0.02
d 0.60 ± 0.02
b 0.50 ± 0.02
c 0.66 ± 0.02
a
C18:1 c12-15 0.40 ± 0.02
b 0.55 ± 0.03
a 0.41 ± 0.03
b 0.56 ± 0.05
a
C18:1 t4-8 0.09 ± 0.01
b 0.25 ± 0.02
a 0.09 ± 0.02
b 0.25 ± 0.01
b
C18:1 t9 0.16 ± 0.01
b 0.29 ± 0.01
a 0.15 ± 0.03
b 0.30 ± 0.01
a
C18:1 t10 0.21 ± 0.02
c 0.28 ± 0.02
b 0.22 ± 0.02
c 0.32 ± 0.01
a
C18:1 t11 (VA) 0.47 ± 0.02
c 4.54 ± 0.13
b 0.51 ± 0.01
c 4.96 ± 0.05
a
C18:1 t12-16 0.81 ± 0.07
c 1.25 ± 0.10
b 0.91 ± 0.03
c 1.44 ± 0.04
a
C18:2 n-6 1.06 ± 0.09
b 1.30 ± 0.06
ab 1.48 ± 0.43
ab 1.73 ± 0.38
a
C18:2 n-6 (t,t) 0.30 ± 0.02
c 0.52 ± 0.04
b 0.35 ± 0.03
c 0.71 ± 0.06
a
C18:2 c9,t11 0.31 ± 0.03
c 2.77 ± 0.13
b 0.32 ± 0.04
c 3.04 ± 0.08
a
C18:2 t11,c13 0.00 ± 0.00
c 0.25 ± 0.01
b 0.00 ± 0.00
c 0.29 ± 0.02
a
C18:2 t9,t11 0.03 ± 0.01
c 0.12 ± 0.00
b 0.01 ± 0.01
d 0.16 ± 0.02
a
C18:2 t11,t13 0.00 ± 0.00
c 0.05 ± 0.00
a 0.00 ± 0.00
c 0.04 ± 0.01
b
C18:3 n-3 0.34 ± 0.03
d 1.27 ± 0.06
b 0.43 ± 0.03
c 1.46 ± 0.02
a
C20:0 0.21 ± 0.11 0.17 ± 0.02 0.20 ± 0.04 0.19 ± 0.03
C20:1 c9 0.02 ± 0.00 0.03 ± 0.01 0.04 ± 0.02 0.03 ± 0.02
C20:3 n-6 0.09 ± 0.01 0.07 ± 0.01 0.09 ± 0.03 0.07 ± 0.02
C20:4 n-6 0.10 ± 0.01
a 0.07 ± 0.00
b 0.10 ± 0.01
a 0.08 ± 0.02
b
C20:5 n-3 0.04 ± 0.01
b 0.11 ± 0.01
a 0.03 ± 0.02
b 0.10 ± 0.02
a
C22:5 n-3 0.09 ± 0.01
b 0.12 ± 0.00
ab 0.08 ± 0.07
b 0.16 ± 0.05
a
∑ SCFA(C4 > C8) 6.58 ± 0.50
a 6.56 ± 0.40
a 0.00 ± 0.00
b 0.00 ± 0.00
b
∑ MCFA(C10 > C14) 20.77 ± 0.98
a 16.15 ± 0.43
c 18.50 ± 0.95
b 14.19 ± 0.45
d
∑ SFA 77.73 ± 1.00
a 62.95 ± 1.17
c 75.25 ± 0.74
b 58.98 ± 0.35
d
∑ MUFA 19.89 ± 0.81
d 30.29 ± 0.93
b 21.67 ± 0.21
c 33.02 ± 0.33
a
∑ PUFA incl. CLA 2.38 ± 0.19
d 6.76 ± 0.25
b 3.07 ± 0.58
c 8.01 ± 0.38
a
∑ PUFA n-3 0.48 ± 0.05
c 1.58 ± 0.06
b 0.56 ± 0.11
c 1.83 ± 0.05
a
∑ PUFA n-6 1.26 ± 0.10
b 1.46 ± 0.06
ab 1.83 ± 0.48
a 1.92 ± 0.38
a
PUFA/SFA 0.03 ± 0.00
d 0.11 ± 0.01
b 0.04 ± 0.01
c 0.14 ± 0.01
a
n-6/n-3 2.60 ± 0.12
b 0.93 ± 0.01
c 3.26 ± 0.23
a 1.05 ± 0.19
c
∑ SFA+tFA 79.78 ± 0.86
a 70.08 ± 0.90
c 77.49 ± 0.75
b 66.96 ± 0.30
d
∑ C18:1 (t) 1.74 ± 0.13
c 6.61 ± 0.26
b 1.88 ± 0.09
c 7.28 ± 0.07
a
C18:1 t9/t11 0.35 ± 0.01
a 0.06 ± 0.00
c 0.30 ± 0.05
b 0.06 ± 0.00
c
∑ CLA 0.34 ± 0.03
c 3.19 ± 0.13
b 0.33 ± 0.04
c 3.55 ± 0.09
a
VA + C18:2 c9,t11 0.78 ± 0.04
c 7.31 ± 0.26
b 0.83 ± 0.04
c 8.00 ± 0.13
a
∑ BCFA 1.75 ± 0.05
d 2.39 ± 0.08
b 2.11 ± 0.06
c 2.80 ± 0.03
a
FA distribution of milk lipids from TAG (ML conventional and ML Alpine) before preparation (A) to FFA-mixtures suitable for cellular experiments, FA distribution
of milk lipids as FFA-mixtures used for incubation of cells after saponification, extraction and solution (B) of milk lipids (FFA) in ethanol. Means (n = 6) of FAME
[%] significantly differ without the same letter
(a, b, c, d), two-way ANOVA Tukey post hoc test P < 0.05.
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acter, we considered this milk as being appropriate for
the comparative study of complex milk lipids in vitro.
The treatment of MLcon and MLalp for the production
of an ethanolic FFA solution (100 mM) led to a signifi-
cant loss of SCFA (short-chain fatty acid) and a decrease
in MCFA (middle-chain fatty acid) levels that resulted in
a redistribution and percentage increase of the majority
of FA (Table 1B). However, independent of the treat-
ment procedure, a fraction of the FA, namely stearic
acid (C18:0), arachidic acid (C20:0), gondoic acid (C20:1
c11), and dihomo-g-linolenic acid (C20:3 n-6) remained
generally unaffected.
The measurement with Ag
+-HPLC ought to provide
information relating to CLA isomer distribution and
may help to elucidate the consequences of the treatment
(Table 2). The distribution of CLA isomers differed sig-
nificantly. As determined by GC analysis, c9,t11-CLA
was the major isomer. The portion of this isomer with
regards to CLA distribution was higher for MLalp com-
pared to MLcon (Tables 1 and 2). The second most
abundant CLA isomers of MLcon and MLalp were t7,c9-
CLA (9%) and t11,c13-CLA (8%), respectively. The indi-
vidual ratios of t11,c13-CLA/t7,c9-CLA significantly dif-
fered by a factor of 17 and indicated an Alpine origin of
the lipids as well as grazing on mountain pasture, as
shown earlier [10]. Notably, the fraction of all-cis and
all-trans-CLA of MLcon was significantly higher com-
pared to MLalp. Significant changes of the CLA profile
during sample preparation of milk lipids to FFA-MLcon/
alp were not observed (Table 2).
Fatty acid analysis of HT-29 cells
Incubation of HT-29 cells with complex lipids in the
form of FFA derivatives prerequisites an analysis of the
degree of FA incorporation allowing evaluation of the
influence of different FA profiles on cellular lipid meta-
bolism. FFA Concentrations of 100 μM and 200 μM
were chosen because preliminary experiments showed
no significant influence of these values on the viability
of HT-29 cells. Results revealed that treatment with
MLcon/alp led to a significant alteration of total cellular
lipid content including FA distribution at 8 h and 24 h
of incubation. Absolute quantitative determination
showed a dose-dependent increase of the major FA
C16:0 and C18:1 c9( μg FA/mg cellular protein) at 8 h
and 24 h of incubation (Figure 1). However, after 24 h
of incubation the amount of total cellular lipids as mea-
sured for the two FA (μg FA/mg cellular protein)
decreased in a time-dependent manner with the excep-
tion of C16:0 and C18:1 c9 after incubation with 200
μMo fM L con,. Cellular lipid content of control did not
Table 2 Fatty acid distribution of CLA isomers in different milk lipids
AB
MLcon MLalp MLcon MLalp
CLA FAME [%] Mean SD Mean SD Mean SD Mean SD
t12,t14 2.36 ± 0.08
a 0.96 ± 0.01
b 2.34 ± 0.16
a 1.00 ± 0.02
b
t11,t13 4.19 ± 0.09
a 1.86 ± 0.05
b 4.05 ± 0.16
a 1.92 ± 0.06
b
t10,t12 0.95 ± 0.07
a 0.17 ± 0.04
b 0.97 ± 0.09
a 0.33 ± 0.09
b
t9,t11 2.68 ± 0.24
b 0.54 ± 0.03
c 3.27 ± 0.16
a 0.85 ± 0.20
c
t8,t10 1.41 ± 0.08
a 0.19 ± 0.03
b 1.53 ± 0.21
a 0.22 ± 0.09
b
t7,t9 0.42 ± 0.03
a 0.07 ± 0.03
b 0.41 ± 0.10
a 0.06 ± 0.03
b
∑ trans,trans 12.18 ± 0.24
a 3.84 ± 0.07
b 12.69 ± 0.74
a 4.42 ± 0.44
b
t11,c13 1.51 ± 0.15
b 7.88 ± 0.02
a 1.29 ± 0.08
b 7.83 ± 0.09
a
c11,t13 0.39 ± 0.14 0.17 ± 0.03 0.25 ± 0.12 0.24 ± 0.07
t10,c12 0.51 ± 0.03
ab 0.07 ± 0.04
b 0.74 ± 0.26
a 0.32 ± 0.38
ab
c9,t11 74.46 ± 0.59
b 84.57 ± 0.19
a 74.64 ± 0.63
b 83.77 ± 0.86
a
t8,c10 0.91 ± 0.25 0.60 ± 0.13 1.21 ± 0.28 0.61 ± 0.27
t7,c9 8.97 ± 0.28
a 2.64 ± 0.23
b 8.39 ± 0.09
a 2.56 ± 0.34
b
∑ cis,trans/trans,cis 86.90 ± 0.25
b 95.99 ± 0.02
a 86.62 ± 0.75
b 95.39 ± 0.42
a
c11,c13 0.07 ± 0.04 0.10 ± 0.06 0.10 ± 0.06 0.09 ± 0.03
c10,c12 0.10 ± 0.08 - 0.05 ± 0.01 -
c9,c11 0.67 ± 0.20
a 0.07 ± 0.01
c 0.54 ± 0.30
ab 0.10 ± 0.01
ab
c8,c1 0 -- --
∑ cis/cis 0.84 ± 0.08
a 0.17 ± 0.06
b 0.69 ± 0.33
a 0.18 ± 0.02
b
t11,c13/t7,c9 0.17 ± 0.02
b 3.00 ± 0.26
a 0.15 ± 0.01
b 3.10 ± 0.48
a
FA distribution of milk lipids from TAG (ML conventional and ML Alpine) before preparation (A) to FFA-mixtures suitable for cellular experiments, FA distribution
of milk lipids as FFA-mixtures used for incubation of cells after saponification, extraction and solution (B) of milk lipids (FFA) in ethanol. Means (n = 6) of FAME
[%] significantly differ without the same letter
(a, b, c, d), two-way ANOVA Tukey post hoc test P < 0.05.
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content of untreated cells (control), the treatment with
MLalp and MLcon led to a dose-dependent increase for
both FA by 2 fold (MLalp;8ha n d2 4ho fi n c u b a t i o n ) ,
by 1.5 fold (MLcon;8h )a n db y3f o l d( M L con;2 4h ) ,
respectively. Consequently, the main characteristics of
the different milk lipids were reflected by these two
important major FA. Thus, MLcon (200 μMa t2 4h )l e d
to the significantly highest concentration of one SFA
(C16:0), whereas, in contrast, MLalp caused the signifi-
cantly highest concentration of one MUFA (C18:1 c9)
(200 μM at 8 h). The sum of both FA reflected a dose-
dependent increase (Figure 1).
Relative quantitative analysis supported this observa-
tion and showed a significant alteration of cell lipid
composition (Tables 3 and 4). The percentage of SFA
was considerably increased after incubation with the
milk lipids compared to the control. Typically, MLcon
led to higher increase of SFA compared to MLalp.
Otherwise, MLalp led to higher portions of MUFA com-
pared to MLcon,b u tn o tt ot h ec o n t r o l .A d d i t i o n a l l y ,
PUFA, including CLA were significantly lower after 8 h
of incubation with MLcon compared to MLalp and the
control, and further decreased after 24 h with MLcon
and control compared to MLalp.N o t a b l y ,P U F A( n - 3
and n-6) were lower after incubation with milk lipids
compared to the control. However, MLcon significantly
increased whereas MLalp significantly decreased the ratio
of n-6/n-3 PUFA. In addition, MLalp showed the highest
dose-dependent portions of CLA, trans-C18:1 and
BCFA in cellular lipids at 8 h and 24 h of incubation
(Tables 3 and 4). Particularly, a doubling of the concen-
tration did not lead to further changes of FA composi-
t i o nf o re i t h e ri n c u b a t ion procedures. C18:1 t11
converted to c9,t11-CLA dose- and time-dependently
through Δ9-desaturation following incubation with
MLalp. Generally, MLalp significantly increased total CLA
compared to MLcon by a factor of 8 (100 μM) and 9
(200 μM). The formation of conjugated metabolites was
found only after incubation with MLalp. Despite the low
percentage of total CLA lipid content, C16:2 c7,t9
increased dose- and time-dependently (Tables 3 and 4).
The CLA composition of cellular lipids after incuba-
tion with the respective milk lipids was investigated
using Ag
+-HPLC (Table 5). Results showed the main
characteristic portions of CLA after 8 h of incubation to
be similar as compared to the distribution of CLA in
intact milk lipids (Tables 2 and 5). Thus, MLcon-treated
cells showed highest portions of all-trans-CLA and all-
cis-CLA as well as decreased levels of cis/trans, trans/
cis-CLA compared to the control and MLalp.T h er a t i o
of t11,c13-CLA/t7,c9-CLA significantly differed after
treatment with milk lipids as mentioned above for the
distribution of MLcon/alp (Tables 2 and 5).
Effects of milk lipids on viability and growth
The effects of lipids from two different milk sources
(MLalp,M L con) on cell viability (CTB assay) and modu-
lation of growth parameters (DAPI assay) were mea-
s u r e da f t e ri n c u b a t i o nf o r2 4h ,4 8ha n d7 2h ,
respectively (Figure 2). Viability and growth of HT-29
cells were reduced in a dose- and time-dependent

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Page 6 of 14manner. In particular, concentrations of 5 μM-5 0μM
showed no effects compared to control. MLcon and
MLalp significantly reduced cell growth after treatment
with 150 μM (24 h) to 75% and 72%, respectively.
Viability was significantly decreased after 250 μMa t2 4
h of incubation. After 48 h, both lipids caused a
decrease of cell viability and growth at 150 μM. After 48
ha n d7 2ho fi n c u b a t i o n ,t h i sw a sa l s oo b s e r v e df o r
Table 3 Fatty acid distribution of cellular lipids treated with different milk lipids at 8 h
Control MLcon MLalp
0.25% EtOH 100 μM 200 μM 100 μM 200 μM
FAME [%] Mean SD Mean SD Mean SD Mean SD Mean SD
C14:0 1.58 ± 0.39
d 6.38 ± 0.87
bc 7.96 ± 0.94
a 5.38 ± 0.57
c 6.81 ± 0.51
ab
C14:1 c9 0.10 ± 0.04
d 0.24 ± 0.05
bc 0.33 ± 0.05
a 0.22 ± 0.05
c 0.30 ± 0.03
ab
C15:0 0.25 ± 0.03
d 1.02 ± 0.09
bc 1.18 ± 0.08
a 1.08 ± 0.09
c 1.28 ± 0.07
ab
C16:0 20.92 ± 0.95
d 34.53 ± 1.89
b 36.96 ± 1.35
a 26.52 ± 1.14
c 26.77 ± 0.99
c
C16:1 c9 12.75 ± 0.74
a 8.11 ± 0.80
b 6.64 ± 0.52
c 7.11 ± 0.51
bc 5.58 ± 0.36
d
C16:2 t7,c9 - - - 0.03 ± 0.01
b 0.05 ± 0.01
a
C17:0 0.44 ± 0.03
c 0.64 ± 0.04
b 0.63 ± 0.02
b 0.69 ± 0.04
a 0.67 ± 0.02
ab
C18:0 13.02 ± 0.47
a 10.23 ± 0.29
b 9.34 ± 0.63
c 10.13 ± 0.37
b 8.66 ± 0.27
c
C18:1 c9 34.32 ± 0.82
a 25.93 ± 1.71
c 25.02 ± 1.66
c 29.23 ± 1.32
b 29.05 ± 1.34
b
C18:1 c11 3.25 ± 0.18
a 1.85 ± 0.24
b 1.47 ± 0.08
c 1.90 ± 0.12
b 1.56 ± 0.07
c
C18:1 c12-15 - 0.31 ± 0.10
b 0.39 ± 0.09
ab 0.42 ± 0.13
ab 0.48 ± 0.11
a
C18:1 t4-8 - 0.03 ± 0.01
bc 0.03 ± 0.01
bc 0.08 ± 0.06
ab 0.11 ± 0.05
a
C18:1 t9 - 0.10 ± 0.03
b 0.10 ± 0.04
b 0.16 ± 0.04
ab 0.19 ± 0.07
a
C18:1 t10 - 0.14 ± 0.04
b 0.18 ± 0.03
b 0.19 ± 0.04
b 0.25 ± 0.05
a
C18:1 t11 (VA) - 0.27 ± 0.03
c 0.34 ± 0.03
c 2.50 ± 0.20
b 3.32 ± 0.16
a
C18:1 t12-16 - 0.42 ± 0.14
c 0.54 ± 0.18
bc 0.75 ± 0.19
ab 0.92 ± 0.20
a
C18:2 n-6 2.65 ± 0.13
a 2.08 ± 0.05
cd 2.04 ± 0.17
d 2.28 ± 0.07
b 2.25 ± 0.11
bc
C18:2 n-6 (t,t) - 0.21 ± 0.06
d 0.29 ± 0.03
c 0.43 ± 0.04
b 0.54 ± 0.03
a
C18:2 c9,t11 0.09 ± 0.01
e 0.32 ± 0.01
d 0.37 ± 0.03
c 2.47 ± 0.07
b 3.18 ± 0.14
a
C18:2 t11,c13 - - - 0.18 ± 0.02
b 0.26 ± 0.02
a
C18:2 t9,t11 - 0.03 ± 0.01
cd 0.04 ± 0.01
c 0.18 ± 0.02
b 0.24 ± 0.03
a
C18:3 n-3 0.22 ± 0.03
d 0.33 ± 0.02
c 0.42 ± 0.05
c 0.96 ± 0.02
b 1.31 ± 0.09
a
C20:0 0.38 ± 0.03
a 0.30 ± 0.02
b 0.24 ± 0.03
c 0.28 ± 0.02
b 0.20 ± 0.02
c
C20:1 c9 0.33 ± 0.07
a 0.17 ± 0.04
bc 0.15 ± 0.02
d 0.23 ± 0.04
b 0.18 ± 0.02
bc
C20:3 n-6 1.19 ± 0.14
a 0.63 ± 0.05
b 0.49 ± 0.04
cd 0.58 ± 0.06
bc 0.42 ± 0.05
d
C20:4 n-6 2.38 ± 0.25
a 1.20 ± 0.09
b 0.86 ± 0.05
c 1.13 ± 0.13
b 0.77 ± 0.09
c
C20:5 n-3 0.70 ± 0.05
a 0.35 ± 0.04
bc 0.27 ± 0.02
d 0.39 ± 0.03
b 0.31 ± 0.03
cd
C22:5 n-3 1.34 ± 0.15
a 0.70 ± 0.11
b 0.53 ± 0.06
c 0.69 ± 0.08
bc 0.54 ± 0.07
bc
C22:6 n-3 1.76 ± 0.16
a 0.82 ± 0.11
b 0.58 ± 0.05
c 0.78 ± 0.10
b 0.53 ± 0.07
c
∑ SFA 38.65 ± 0.88
a 55.47 ± 2.59
b 58.67 ± 1.83
a 46.78 ± 1.59
c 47.29 ± 1.66
c
∑ MUFA 50.84 ± 0.34
b 37.69 ± 2.28
c 35.30 ± 1.49
c 42.91 ± 1.34
b 42.07 ± 1.22
b
∑ PUFA incl. CLA 10.51 ± 0.86
a 6.84 ± 0.47
b 6.03 ± 0.44
b 10.31 ± 0.44
a 10.64 ± 0.56
a
∑ PUFA n-3 4.14 ± 0.36
a 2.31 ± 0.28
c 1.88 ± 0.16
c 2.95 ± 0.21
b 2.82 ± 0.22
b
∑ PUFA n-6 6.28 ± 0.51
a 3.98 ± 0.18
bc 3.46 ± 0.25
d 4.07 ± 0.25
b 3.54 ± 0.23
cd
PUFA/SFA 0.27 ± 0.03
a 0.12 ± 0.01
c 0.10 ± 0.01
c 0.22 ± 0.02
b 0.23 ± 0.02
b
n-6/n-3 1.52 ± 0.06
b 1.74 ± 0.17
a 1.85 ± 0.07
a 1.38 ± 0.03
bc 1.26 ± 0.02
c
∑ SFA + tFA 38.65 ± 0.88
d 56.71 ± 2.73
b 60.23 ± 2.06
a 50.97 ± 2.04
c 52.73 ± 1.91
c
∑ C18:1 (t) - 0.96 ± 0.18
c 1.18 ± 0.26
c 3.68 ± 0.46
b 4.79 ± 0.38
a
C18:1 t9,t11 - 0.37 ± 0.10
a 0.28 ± 0.09
a 0.06 ± 0.01
b 0.06 ± 0.02
b
∑ CLA 0.09 ± 0.01
d 0.35 ± 0.02
c 0.41 ± 0.04
c 2.83 ± 0.07
b 3.68 ± 0.15
a
VA + C18:2 c9,t11 0.09 ± 0.01
d 0.59 ± 0.04
c 0.71 ± 0.03
c 4.97 ± 0.25
b 6.50 ± 0.30
a
∑ BCFA 0.44 ± 0.12
d 1.59 ± 0.15
c 1.83 ± 0.13
b 1.97 ± 0.16
b 2.38 ± 0.14
a
FA distribution of HT-29 cells after incubation with milk lipids (ML conventional and ML Alpine) given as FFA-mixtures in ethanol. Means (n = 6) of FAME [%]
significantly differ without the same letter
(a, b, c, d), two-way ANOVA Tukey post hoc test P < 0.05.
Degen et al. Lipids in Health and Disease 2011, 10:131
http://www.lipidworld.com/content/10/1/131
Page 7 of 14MLcon at 100 μM (Figure 2). There were no significant
differences between the milk lipids regarding the influ-
ence on viability and growth of HT-29 cells at any time
point (Figure 2).
Discussion
Naturally and synthetically derived CLA has been shown
to act against artherogenesis, hypertension, diabetes,
inflammation and cancer [26,27]. Whereas numerous
Table 4 Fatty acid distribution of cellular lipids treated with different milk lipids at 24 h
Control MLcon MLalp
0.25% EtOH 100 μM 200 μM 100 μM 200 μM
FAME [%] Mean SD Mean SD Mean SD Mean SD Mean SD
C14:0 1.67 ± 0.32
d 6.26 ± 0.34
b 8.33 ± 0.61
a 5.36 ± 0.28
c 6.86 ± 0.46
b
C14:1 c9 0.17 ± 0.06
c 0.55 ± 0.09
ab 0.67 ± 0.15
a 0.46 ± 0.06
b 0.54 ± 0.07
ab
C15:0 0.21 ± 0.01
c 0.81 ± 0.06
b 1.04 ± 0.04
a 0.85 ± 0.04
b 1.12 ± 0.05
a
C16:0 20.48 ± 0.71
d 30.34 ± 1.27
b 34.36 ± 1.34
a 24.56 ± 0.65
c 25.57 ± 0.29
c
C16:1 c9 15.44 ± 0.97
a 11.82 ± 1.23
b 9.45 ± 1.09
c 9.31 ± 0.95
c 6.96 ± 0.73
d
C16:2 t7,c9 - - - 0.07 ± 0.01
b 0.08 ± 0.00
a
C17:0 0.32 ± 0.01
a 0.54 ± 0.04
c 0.59 ± 0.03
b 0.59 ± 0.04
b 0.68 ± 0.03
d
C18:0 10.97 ± 0.89
a 9.39 ± 0.32
b 8.77 ± 0.34
b 9.03 ± 0.21
b 8.71 ± 0.25
b
C18:1 c9 36.95 ± 0.87
a 28.67 ± 0.64
d 26.09 ± 0.27
e 31.63 ± 0.99
b 30.27 ± 0.34
c
C18:1 c11 3.04 ± 0.20
a 1.77 ± 0.15
b 1.33 ± 0.09
a 1.84 ± 0.05
b 1.39 ± 0.11
a
C18:1 c12-15 - 0.29 ± 0.15
a 0.38 ± 0.07
a 0.41 ± 0.13
a 0.43 ± 0.10
a
C18:1 t4-8 - 0.02 ± 0.01
bc 0.04 ± 0.02
bc 0.07 ± 0.04
ab 0.10 ± 0.05
a
C18:1 t9 - 0.09 ± 0.02
c 0.12 ± 0.03
bc 0.15 ± 0.04
ab 0.20 ± 0.06
a
C18:1 t10 - 0.10 ± 0.02
b 0.14 ± 0.03
b 0.14 ± 0.04
b 0.20 ± 0.03
a
C18:1 t11 (VA) - 0.18 ± 0.04
c 0.28 ± 0.05
c 1.86 ± 0.25
b 2.73 ± 0.27
a
C18:1 t12-16 - 0.35 ± 0.09
c 0.58 ± 0.08
b 0.56 ± 0.13
b 0.81 ± 0.18
a
C18:2 n-6 2.13 ± 0.18
a 1.91 ± 0.12
bc 1.73 ± 0.07
c 2.13 ± 0.09
a 2.00 ± 0.04
ab
C18:2 n-6 (t,t) - 0.13 ± 0.05
d 0.22 ± 0.03
c 0.28 ± 0.05
b 0.42 ± 0.03
a
C18:2 c9,t11 0.07 ± 0.02
d 0.35 ± 0.02
c 0.40 ± 0.02
c 2.90 ± 0.27
b 3.57 ± 0.18
a
C18:2 t11,c13 - - - 0.15 ± 0.02
b 0.21 ± 0.02
a
C18:2 t9,t11 - 0.04 ± 0.01
c 0.04 ± 0.01
c 0.19 ± 0.02
b 0.21 ± 0.02
a
C18:3 n-3 0.20 ± 0.03
d 0.35 ± 0.03
c 0.39 ± 0.03
c 1.03 ± 0.09
b 1.26 ± 0.06
a
C20:0 0.35 ± 0.02
a 0.30 ± 0.02
b 0.28 ± 0.01
bc 0.30 ± 0.01
b 0.27 ± 0.01
c
C20:1 c9 0.41 ± 0.05
a 0.19 ± 0.04
cd 0.15 ± 0.00
d 0.26 ± 0.02
b 0.21 ± 0.01
bc
C20:3 n-6 0.97 ± 0.12
a 0.55 ± 0.01
b 0.38 ± 0.01
c 0.53 ± 0.02
b 0.36 ± 0.02
c
C20:4 n-6 1.82 ± 0.19
a 1.00 ± 0.02
b 0.66 ± 0.03
c 0.95 ± 0.04
b 0.63 ± 0.04
c
C20:5 n-3 0.53 ± 0.05
a 0.29 ± 0.02
bc 0.21 ± 0.01
d 0.33 ± 0.02
b 0.25 ± 0.01
cd
C22:5 n-3 1.04 ± 0.15
a 0.59 ± 0.03
b 0.42 ± 0.01
c 0.62 ± 0.05
b 0.43 ± 0.03
c
C22:6 n-3 1.31 ± 0.12
a 0.70 ± 0.03
b 0.45 ± 0.03
c 0.70 ± 0.05
b 0.43 ± 0.04
c
∑ SFA 35.66 ± 1.27
e 49.81 ± 1.52
b 55.66 ± 1.15
a 43.14 ± 1.00
d 45.98 ± 0.53
c
∑ MUFA 56.10 ± 1.15
a 44.15 ± 1.60
c 39.35 ± 1.17
d 46.84 ± 0.86
b 43.99 ± 0.63
c
∑ PUFA incl. CLA 8.24 ± 0.78
b 6.04 ± 0.20
c 4.99 ± 0.06
d 10.05 ± 0.57
a 10.03 ± 0.17
a
∑ PUFA n-3 3.20 ± 0.34
a 2.01 ± 0.07
d 1.51 ± 0.04
e 2.78 ± 0.17
b 2.47 ± 0.04
c
∑ PUFA n-6 4.97 ± 0.47
a 3.51 ± 0.13
b 2.82 ± 0.06
c 3.67 ± 0.13
b 3.07 ± 0.04
c
PUFA/SFA 0.23 ± 0.03
a 0.12 ± 0.00
b 0.09 ± 0.00
c 0.23 ± 0.02
a 0.22 ± 0.00
a
n-6/n-3 1.56 ± 0.07
c 1.75 ± 0.07
b 1.87 ± 0.07
a 1.32 ± 0.03
d 1.25 ± 0.01
d
∑ SFA + tFA 35.66 ± 1.27
d 50.75 ± 1.62
b 57.13 ± 1.33
a 46.28 ± 1.17
c 50.56 ± 1.04
b
∑ C18:1 (t) - 0.74 ± 0.16
c 1.16 ± 0.18
c 2.78 ± 0.45
b 4.05 ± 0.55
a
C18:1 t9/t11 - 0.51 ± 0.07
a 0.42 ± 0.07
b 0.08 ± 0.02
c 0.07 ± 0.02
c
∑ CLA 0.07 ± 0.02
d 0.39 ± 0.02
c 0.44 ± 0.02
c 3.26 ± 0.33
b 3.99 ± 0.17
a
VA + C18:2 c9,t11 0.07 ± 0.02
d 0.52 ± 0.05
cd 0.68 ± 0.06
c 4.75 ± 0.52
b 6.30 ± 0.40
a
∑ BCFA 0.37 ± 0.10
d 1.36 ± 0.13
c 1.68 ± 0.10
b 1.72 ± 0.17
b 2.16 ± 0.11
a
FA distribution of HT-29 cells after incubation with milk lipids (ML conventional and ML Alpine) given as FFA-mixtures in ethanol. Means (n = 6) of FAME [%]
significantly differ without the same letter
(a, b, c, d), two-way ANOVA Tukey post hoc test P < 0.05.
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Page 8 of 14studies indicate anticarcinogenic effects mostly due to
single isomers, such as c9,t11-CLA or t10,c12-CLA
[9,28] in different model systems, little is known about
both the mode of action of isolated CLA isomers and
their effectiveness when applied as a natural composi-
tion. Therefore, it is important to mimic the absorption
of functional lipid ingredients in human gut with milk
and dairy products. To test the potentially synergetic
effects of FFA mixtures in vitro, HT-29 cells were trea-
ted with Alpine milk lipids richer in CLA, the precursor
of CLA (C18:1 t11), and n-3 PUFA than conventional
milk lipids.
First, we established an in vitro method that enabled
us to test FFA mixtures of milk lipids. Alterations in
milk lipid characteristics were monitored by this
method. The SCFA fraction was excluded because levels
of butyrate and other SCFA were not significantly differ-
ent between the two types of milk, i.e., MLalp,M L con
(Table 1). Furthermore, treatment with a mixture of
PUFA and butyrate enhanced apoptosis of HT-29 cells
[29]. Since the human gut is the main SCFA source of
butyrate [30], we investigated potentially anticarcino-
genic properties of milk fat in vitro considering only FA
of chain lengths of over C8:0. Short saponification times
(30 min) at a higher temperature (70°C) instead of the
previously reported saponification conditions were more
successful [31]. FFA were separated from total lipids
and the prevention of oxidative artifacts, especially of
the CLA isomers was proven by means of Ag
+-HPLC
analysis (Table 2). Although larger fractions of FA were
enriched as a result of this method, the composition of
the milk lipids was preserved and no effect on the distri-
bution of important FA such as CLA isomers was
detectable (Tables 1 and 2). Differences in the origin
and type of feed were reflected by the respective milk
lipid composition (Table 1). The results confirmed the
typical FA distribution of MLalp and represented grazing
food conditions in the Alps as described earlier [10,32].
Moreover, our results attested fatty acid distribution of
MLcon to intensive feeding conditions [11].
In addition to the fact that effects of a mixture of
lipids of ruminant origin have been poorly studied in
vitro, incorporation of milk lipid FA into cellular lipids
has also been scantily investigated to date. However, the
treatment of HT-29 cells involving 8 h and 24 h of incu-
bation described herein verified not only the uptake and
utilization of the FA mixtures, but also indicated a rela-
tionship of FA distribution and growth inhibition in
HT-29 cells. Cell lipid content and FA composition
were affected differently depending on treatment with
MLcon or MLalp. Whereas both milk lipids led to a com-
parable increase of total lipids, the ratio of the
Table 5 CLA isomers in cellular lipids of HT-29 treated with different milk lipids at 8 h
Control MLcon MLalp
0.25% EtOH 100 μM 200 μM 100 μM 200 μM
CLA FAME [%] Mean SD Mean SD Mean SD Mean SD Mean SD
t12,t1 4 -----
t11,t13 - 2.63 ± 0.71
a 2.76 ± 0.26
a 1.26 ± 0.14
b 1.31 ± 0.06
b
t10,t12 - 0.69 ± 0.23
a 0.82 ± 0.09
a 0.24 ± 0.09
b 0.26 ± 0.09
b
t9,t11 3.15 ± 1.28
a 3.08 ± 0.49
a 3.35 ± 0.51
a 1.18 ± 0.35
b 1.14 ± 0.34
b
t8,t10 - 0.28 ± 0.15
ab 0.47 ± 0.16
a 0.02 ± 0.01
bc 0.11 ± 0.02
bc
t7,t9 2.86 ± 0.79
a 0.89 ± 0.28
b 0.73 ± 0.08
b 0.09 ± 0.05
b 0.05 ± 0.01
b
∑ trans, trans 6.02 ± 2.06
bc 8.38 ± 1.19
ab 9.68 ± 0.30
a 3.48 ± 0.53
c 3.57 ± 0.50
c
t11,c13 4.88 ± 3.15
ab 3.59 ± 1.20
ab 1.81 ± 0.30
b 6.54 ± 0.47
a 6.83 ± 0.34
a
c11,t13 3.00 ± 1.89
a 1.80 ± 0.93
ab 1.17 ± 0.25
ab 0.31 ± 0.06
b 0.36 ± 0.10
b
t10,c12 3.82 ± 1.39
a 3.48 ± 1.11
b 1.61 ± 0.75
ab 0.42 ± 0.27
b 0.22 ± 0.15
b
c9,t11 77.28 ± 3.25
b 74.65 ± 0.80
a 76.12 ± 0.98
b 86.66 ± 1.17
a 87.14 ± 0.80
a
t8,c10 0.63 ± 0.45
ab 0.78 ± 0.58
ab 1.20 ± 0.25
a 0.44 ± 0.10
ab 0.18 ± 0.10
b
t7,c9 4.38 ± 1.55
bc 6.09 ± 1.58
cd 7.18 ± 0.55
a 1.82 ± 0.20
cd 1.44 ± 0.11
d
∑ cis,trans/trans,cis 93.98 ± 2.06
a 90.39 ± 1.23
b 89.09 ± 0.38
b 96.19 ± 0.61
a 96.17 ± 0.59
a
c11,c13 - - - 0.08 ± 0.02 0.03 ± 0.00
c10,c1 2 -----
c9,c11 - 1.23 ± 0.10
a 1.18 ± 0.09
a 0.26 ± 0.08
b 0.23 ± 0.09
b
c8,c1 0 -----
∑ cis/cis - 1.23 ± 0.10
a 1.18 ± 0.09
a 0.34 ± 0.09
b 0.26 ± 0.09
b
t11,c13/t7,c9 1.33 ± 1.25
b 0.64 ± 0.34
b 0.25 ± 0.06
b 3.63 ± 0.46
a 4.77 ± 0.55
a
CLA distribution of HT-29 cells after incubation with milk lipids (ML conventional and ML Alpine) given as FFA-mixtures in ethanol. Means (n = 6) of FAME[ % ]
significantly differ without the same letter
(a, b, c, d), two-way ANOVA Tukey post hoc test P < 0.05.
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Page 9 of 14determined major FA (C16:0/C18:1 c9 μg FA/mg pro-
tein) differed between MLcon and MLalp (Figure 1). By
simply determining C16:0 and C18:1 c9 by means of
GC-FID, the different origins of applied milk lipids and
type of feeding could be distinguished. Acquisition of
total major FA with total cellular protein yielded a
decrease of FA after 24 h. Thus, a complete
incorporation of milk lipids even after 8 h can be
assumed (Figure 1).
Relative quantitative analysis of total cellular lipids fol-
lowing incubation with milk confirmed the high SFA
proportion of total cellular lipids (Tables 3 and 4). Both
milk lipids, MLcon more than MLalp, led to an inversion
of the SFA/MUFA ratio compared to control at 8 h.
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Figure 2 Effects of milk lipids on viability and growth of HT-29 cells. Cell viability was measured by means of the CTB assay (left; A 24 h, B
48 h, C 72 h) and growth parameter of the cells was measured by means of DAPI assay (right; D 24 h, E 48 h, F 72 h). Means (n = 6) are
significantly different from control, one-way ANOVA Dunnett post hoc test (*) P < 0.1, * P < 0.05, ** P < 0.001, *** P < 0.0001.
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Page 10 of 14Notably, incubation with MLalp showed prolonged per-
centage of PUFA compared to MLcon and control within
cellular lipid distribution at 24 h. Generally, a doubling
of the milk lipid concentration did not lead to a dou-
bling of potentially favorable FA such as CLA and n-3
PUFA as shown by absolute quantitative analysis of
C16:0 and C18:1 c9. This observation emphasizes the
contrast to other investigations in which single purified
isomers were used and showed a 2 fold increase of the
administrated single FA in cellular lipids corresponding
to the doubling of the FA concentration [33,34]. How-
ever, the absolute quantitative analysis in the present
study showed a dose-dependent doubling of the major
FA such as C16:0 and C18:1 c9. This important out-
come strongly suggests that total CLA and other
rumen-specific FA (C18:1 t11, BCFA) might be also
doubled in a dose-dependent manner. Moreover, the
results herein confirm that incubation of HT-29 cells
with different milk lipids led to the incorporation of
CLA into cellular lipids which remained consistent,
although the majority of PUFA decreased time-depen-
dently. A similar observation was made with C18:3 n-3
(Tables 3 and 4). Finally, the conversion of C18:1 t11 to
c9,t11-CLA also contributed to an enhancement of total
CLA in cellular lipids. Nevertheless, it remains question-
able whether the daily consumption of Alpine milk and
Alpine dairy products can raise the percentage of CLA
into cellular lipids in vivo compared to in vitro.H o w -
ever, elevated amounts of total CLA and the CLA pre-
cursor C18:1 t11 in the tested MLalp can positively
contribute to improve cellular levels of CLA in vivo.
Thus, future human studies should further investigate if
an equal intake of MLalp compared to MLcon leads to 8
fold higher values of total CLA in cellular lipids as
shown by the results of this study (Tables 3 and 4).
Anticancer activity of CLA was shown to be associated
with modulation of cellular signal transduction
[28,35,36]. Hence, it cannotb ee x c l u d e dt h a t8 - 9f o l d
lower amounts of CLA in MLcon similarly influence cel-
lular signaling pathways after incubation. Accordingly,
these results can plausibly explain why a low concentra-
tion of between 0.1% and 1% CLA in the rodent diet
was sufficient to produce anticarcinogenic effects
[37,38].
The remarkable difference in the ratio of t11,c13-
CLA/t7,c9-CLA was determined by means of Ag
+-HPLC. This ratio can be used as a prospective marker
for application of milk lipids with Alpine origin in a cel-
lular model (Table 5). However, the influence of differ-
ent CLA profiles and minor isomers such as t11,c13-
CLA of Alpine milk on cellular lipid metabolism
remains unclear.
Information on the interaction of conjugated fatty
acids on FA metabolism is derived from the analysis of
directly formed metabolites of CLA isomers (e.g. conju-
gated dienes; CD16:2, CD20:2, CD22:2) [39]. Analysis of
these metabolites is important as it cannot be excluded
that they also exhibit specific biological activity. For
example, c9,t11-CLA can be metabolized to C16:2 c7,t9
by b-oxidation [39]. We found the metabolite C16:2 c7,
t9 immediately following treatment with MLalp (Tables
3 and 4) at a percentage of below 0.1%. Moreover, the
dose- and time-dependent b-oxidation of the major c9,
t11-CLA isomer by HT-29 cells was evident (Tables 3
a n d4 ) .A l t h o u g h ,i tc a n n o tb ee x c l u d e dt h a to t h e r
metabolites could also be formed after incubation with
MLalp, it is likely that concentrations of these metabo-
lites would be extremely low.
Distribution of other cellular lipids was, moreover,
affected by incubation with milk lipids. The dose- and
time- dependent decrease of other PUFA such as C20:4
n6 (arachidonic acid) was shown in this study (Tables 3
and 4). This decrease must be interpreted as a dilution
effect because milk lipids are naturally poor in LC-
PUFA (> C20, long-chain). Stimulation experiments
with milk lipids significantly decreased the percentage of
n - 6a sw e l la sn - 3L C - P U F A( T a b l e s3a n d4 )t h o u g h
absolute quantitative reduction remains questionable.
Nevertheless, treatment with milk lipids [16] or CLA
isomers [40] can partially inhibit conversion of LC-
PUFA such as C20:4 n6 to eicosanoids, which are
important FA derivatives that negatively affect tumori-
genesis [41].
Viability and growth of the cells was reduced in a
dose- and time-dependent manner on treatment with
the two different milk lipids. However, there was no sig-
nificant difference between the treatment with MLcon
and MLalp on these two parameter s .H e n c e ,i tc a nb e
concluded that naturally occurring higher amounts of
beneficial anticarcinogenic compounds like CLA, CLA
precursor (C18:1 t11), and n-3 PUFA in Alpine milk fat
did not increase anticarcinogenic activity of milk lipids
in HT-29 cells at all. Generally, synergistic effects can-
not be excluded when cells are treated with a mixture
of lipids. Our results confirm data from an in vitro
s t u d yo fD eL aT o r r eet al. (2006) showing that a com-
plete mixture of FA with low CLA content (< 1%)
obtained from beef extract led to stronger growth inhi-
bition of cancer cell lines compared to the fraction com-
prising of CLA-mixtures only. Indeed, FA from beef
extract (100 μM) reduced cell numbers of different cell
lines by 30-70% at 48 h of incubation [17] which was
comparable to our study data. However, treatment of
HT-29 cells with MLalp demonstrated an 8-9 fold
increase of CLA that was not stronger compared to
MLcon. Notably, low concentrations (5 μMa n d1 0μM)
showed no beneficial effects on proliferation of the cell
line since C16:0 and C18:1 c9 are able to enhance
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Page 11 of 14cancer cell growth [42,43]. Physiological concentrations
of total FFA in vivo are reported to range between 400 -
800 μM [44]. No data are available from the literature
regarding the association between consumption of milk
lipids and the resulting plasma concentration. In gen-
eral, it is entirely conceivable that concentrations below
100 μM used herein could result from dietary intake of
ruminant lipids. However, higher concentrations up to
250 μM emphasized the dose-effect relationship of the
descriptive data from the in vitro experiments (Figure 2).
Other milk fat ingredients can also be responsible for
the growth inhibitory effects found in this study. In par-
ticular, a health-beneficial potential was shown for
BCFA (e.g. phytanic acid) in dairy lipids [49]. Treatment
of colon cancer cells with ubiquitin and vitamin D, both
constituents of milk fat, also led to inhibition of cell
growth [50,51]. The repeated and continuous dietary
intake of CLA in vivo showed elevated inhibitory effects
on tumorigenesis [38]. It is, therefore, possible that the
multiday incubation of MLalp at lower concentrations
affect the growth of HT-29 cells differently compared to
MLcon. Further reasons for cell growth inhibition are
likely to emerge, since CLA isomers are capable of indu-
cing apoptosis and affecting cell cycle and DNA synth-
esis [36,52,53]. All-trans-CLA seem to exert increased
growth inhibitory effects compared to CLA isomers with
cis configuration [40,52-54]. Therefore, in further studies
it will be of interest to determine whether FA mixtures
rich in all-trans-CLA support this observation.
Several studies showed a dependency on anticarcino-
genic effects in vitro [33] and in vivo [45-47] due to con-
version of C18:1 t11 to CLA. This conversion of C18:1 t11
occurred immediately after treatment with MLalp in this
study, but did not additionally contribute to growth inhibi-
tion compared to cells incubated with MLcon, which were
low in C18:1 t11 (Table 3). Furthermore, incubation with
MLcon markedly led to a significantly decreased PUFA/
SFA ratio compared to control and MLalp treated cells
(Table 4). The altered ratio was shown to be associated
with increased apoptosis and inhibition of proliferation of
PC-3 prostate cancer cells [48].
Conclusions
This study showed significant changes of cell FA distri-
bution and total amounts of cellular lipids after treat-
ment with milk lipids of conventional or Alpine origin.
Both milk lipid mixtures, in the form of FFA-solutions,
effectively decreased viability and growth of HT-29 cells.
However, concerning the inhibitory potential, no differ-
ences of these milk lipid mixtures were observed. Since
the FA profile of the milk lipids determines the profile
of the cell lipids, it might be promising to extend this
feature to other cell lines. The intake of milk and dairy
products is beneficial to health from the nutritional
point of view, particularly with regards to colorectal
cancer. However, mechanistic studies in vitro are
required to distinguish between potential anticarcino-
genic effects of single major isomers (c9,t11-CLA), single
minor isomers (t11,c13-CLA), and complex lipids and to
verify the efficacy in combination with other fatty acids
and their corresponding matrix.
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